Skip to content
M

Michela Pivetta

Publications (3)

Using Soluble CD38 to Overcome Daratumumab Interference in Pretransfusion Compatibility Testing

Michela Pivetta & Gianluca Gessoni · International Blood Research & Reviews · 2024

Background: CD38 is a protein highly expressed on myeloma (MM) cells that has been shown to be an effective target antigen for monoclonal antibody therapies, so treatment with anti-CD38 monoclonal antibodies is a first line therapy for patients with MM. Although CD38 is weaker ex...

Open access Research Article 10.9734/ibrr/2024/v15i3343

Convalescent Plasma Infusion does not Appear to Change the Prognosis in Italian Patients Hospitalized with Sars-Cov-2 Pneumonia

Gianluca Gessoni, Giovanni Roveroni, Lauretta Moro, Michela Pivetta, Michele Tessarin, Domenico Bagnara, Sara Valverde, Rossi Carla, Coluccia Enza, Collodel Luca, Roberto Valle & Giovanni Carretta · International Blood Research & Reviews · 2023

Aims: This case-control prospective study aimed to describe the effects of COVID convalescent plasma (CCP) on late mortality in hospitalized patients with coronavirus disease 2019 (COVID-19) pneumonia.  Study Design: In this study were enrolled 214 consecutive patients with moder...

Open access Research Article 10.9734/ibrr/2023/v14i2305

Convalescent Plasma Infusion in Italian Hospitalized Patients with Severe COVID 19 Pneumonia: Evaluation of Late Mortality Associated Factors

Gianluca Gessoni, Giovanni Roveroni, Lauretta Moro, Michela Pivetta, Michele Tessarin, Domenico Bagnara, Sara Valverde, Rossi Carla, Coluccia Enza, Collodel Luca, Roberto Valle & Giovanni Carretta · International Blood Research & Reviews · 2023

Background: This was a single center prospective study about factors related with mortality in hospitalized patients with severe COVID-19 pneumonia treated with convalescent plasma (CCP) infusion in Venice Prefecture. Methods: In this study were enrolled all the (376) consecutive...

Open access Research Article 10.9734/ibrr/2023/v14i2302